Ralf Bargou
MD
Director, Comprehensive Cancer Center Mainfranken
👥Biography 个人简介
Dr. Ralf Bargou is one of the inventors and clinical developers of blinatumomab (Blincyto), the first BiTE antibody to receive FDA approval. His landmark early clinical studies in B-ALL demonstrated the potency of CD3 x CD19 BiTE antibodies and established the proof of concept for T-cell engaging bispecifics. His pioneering work catalyzed the entire field of bispecific T-cell engager therapeutics for hematologic malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ralf Bargou 的研究动态
Follow Ralf Bargou's research updates
留下邮箱，当我们发布与 Ralf Bargou（University Hospital Wuerzburg）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment